Add time:07/11/2019         Source:sciencedirect.com

DPP-IV inhibitors have been immersed as promising pathway to treat Type 2 diabetes. Here we have reported designing of coumarin derivatives as DPP-IV inhibitors. Designed compounds have been studied for their binding with DPP-IV enzyme through molecular docking followed by synthesis. All synthesized compounds have been fully characterized and screened for DPP-IV inhibition activity. Two compounds showed very good inhibition at 10 μM concentration.

We also recommend Trading Suppliers and Manufacturers of N-{[(4-Methyl-2-oxo-2H-chromen-7-yl)oxy]-acetyl}glycine (cas 307525-71-9). Pls Click Website Link as below: cas 307525-71-9 suppliers